Adenovirus News and Research RSS Feed - Adenovirus News and Research

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.
PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]
PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. [More]
NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. [More]
RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

The effects of Amyloid beta (Aβ)-Aβ-binding alcohol dehydrogenase (ABAD) may exacerbate Alzheimer's disease pathology. [More]
Researchers create universal flu vaccine

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

RNA interference is a process in which RNA molecules inhibit gene expression. This gene silencing process is controlled by RNA-induced silencing complex or RISC and is initiated by small duplex RNA molecules or miRNA that is present inside cell plasma. [More]
NIH study could offer clues for developing new antiviral treatments

NIH study could offer clues for developing new antiviral treatments

A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections. [More]
Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

When it comes to finding cures for heart disease, scientists at Icahn School of Medicine at Mount Sinai are working to their own beat. They may have developed a tissue model for the human heart that can bridge the gap between animal models and human clinical trial patients. [More]
Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

In recognition of his seminal work on adenoviral vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic, Ronald G. Crystal, MD (Weill Cornell Medical College, Cornell University, New York City), has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Scientists develop tissue model for human heart

Scientists develop tissue model for human heart

When it comes to finding cures for heart disease scientists are working to their own beat. That's because they may have finally developed a tissue model for the human heart that can bridge the gap between animal models and human patients. [More]
Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”. [More]
New form of gene therapy shows promising outcomes for "bubble boy" disease

New form of gene therapy shows promising outcomes for "bubble boy" disease

Researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated as part of an international clinical study of a new form of gene therapy. The mechanism used to deliver the gene therapy is designed to prevent the serious complication of leukemia that arose a decade ago in a similar trial in Europe, when one-quarter of boys treated developed the blood cancer. [More]
Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

... [More]
Scientists estimate minimum of 320,000 viruses in mammals

Scientists estimate minimum of 320,000 viruses in mammals

Scientists estimate that there is a minimum of 320,000 viruses in mammals awaiting discovery. Collecting evidence of these viruses, or even a majority of them, they say, could provide information critical to early detection and mitigation of disease outbreaks in humans. [More]
Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine. [More]
New species of adenovirus can spread from monkey to human, say researchers

New species of adenovirus can spread from monkey to human, say researchers

Adenoviruses commonly infect humans, causing colds, flu-like symptoms and sometimes even death, but now UC San Francisco researchers have discovered that a new species of adenovirus can spread from primate to primate, and potentially from monkey to human. [More]
Researchers identify two promising candidates for development of drugs to combat adenovirus

Researchers identify two promising candidates for development of drugs to combat adenovirus

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have identified two promising candidates for the development of drugs against human adenovirus, a cause of ailments ranging from colds to gastrointestinal disorders to pink eye. [More]
Cell Medica treats first pediatric patient in ASPIRE Trial

Cell Medica treats first pediatric patient in ASPIRE Trial

Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of Cytovir ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation. [More]
Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria. [More]